CVN417
Modify Date: 2024-04-08 12:52:13
CVN417 structure
|
Common Name | CVN417 | ||
|---|---|---|---|---|
| CAS Number | 2919851-73-1 | Molecular Weight | 362.85 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H23ClN4O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CVN417CVN417 is an orally active α6 subunit-containing nAChR antagonist, modulating phasic dopaminergic neurotransmission in an impulse-dependent manner. CVN417 inhibits Ca(2+) effluents mediated by nAChR subunits with IC50s of 0.086 μM (α6), 2.56 μM (α3) and 0.657 μM (α4), respectively. CVN417 attenuates resting tremor in Rodent models, displays the potential to improve movement dysfunction, in conditions such as Parkinson's disease[1]. |
| Name | CVN417 |
|---|
| Description | CVN417 is an orally active α6 subunit-containing nAChR antagonist, modulating phasic dopaminergic neurotransmission in an impulse-dependent manner. CVN417 inhibits Ca(2+) effluents mediated by nAChR subunits with IC50s of 0.086 μM (α6), 2.56 μM (α3) and 0.657 μM (α4), respectively. CVN417 attenuates resting tremor in Rodent models, displays the potential to improve movement dysfunction, in conditions such as Parkinson's disease[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.086 μM (nAChR α6), 2.56 μM (nAChR α3), 0.657 μM (nAChR α4)[1] |
| References |
| Molecular Formula | C18H23ClN4O2 |
|---|---|
| Molecular Weight | 362.85 |